Three subsidiaries of Dabur India—Namaste Laboratories LLC, Dermoviva Skin Essentials Inc, and Dabur International Ltd—are entangled in multiple lawsuits in the US and Canada, accused of causing ovarian cancer, uterine cancer, and other health issues with their hair-relaxer products. The cases, consolidated in Multi-District Litigation (MDL), currently total around 5,400, naming the subsidiaries as defendants. Dabur asserts that the allegations lack substantiation, and the subsidiaries deny liability. Defense costs are anticipated to surpass materiality thresholds, though financial implications are yet undetermined. With 27 subsidiaries, Dabur India reported 26.60% of consolidated revenue from operations in FY 2022-23 from its international business.